Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of intravitreal anti-vascular
endothelial growth factor (anti-VEGF) therapy as primary treatment for ICNV.